Grade My Investments
HomeFree Stock Grades › CDNA

CareDx, Inc (CDNA) Stock Grade

CDNA · Healthcare

B+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.0B
P/E Ratio
Revenue Growth (YoY)
+13.8%
Net Margin
-5.6%
Return on Equity
Dividend Yield
None

About CareDx, Inc's fundamentals

CareDx is a healthcare diagnostics company with a market capitalization of $1.0 billion that has demonstrated revenue growth of 13.8% year-over-year, indicating expansion in its core business. However, the company is currently unprofitable, reporting a net loss with a net margin of -5.6% in its latest annual statement. Despite the accounting losses, CareDx has generated positive free cash flow, suggesting the company is converting some operational activities into cash despite its bottom-line losses. The company does not pay a dividend to shareholders.

Track CDNA free — no credit card required. Live grade + monthly AI report →